| Year |
Citation |
Score |
| 2020 |
Sun BL, Sun X, Casanova N, Garcia AN, Oita R, Algotar AM, Camp SM, Hernon VR, Gregory T, Cress AE, Garcia JGN. Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target. Ebiomedicine. 61: 103059. PMID 33045468 DOI: 10.1016/j.ebiom.2020.103059 |
0.564 |
|
| 2019 |
Algotar A, Hsu CH, Sherry Chow HH, Dougherty S, Babiker HM, Marrero D, Abraham I, Kumar R, Ligibel J, Courneya KS, Thomson C. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy. Jmir Research Protocols. 8: e12579. PMID 30720441 DOI: 10.2196/12579 |
0.629 |
|
| 2018 |
Algotar AM, Algotar K, Berkowitz A, Sanft TB. Disconnect between physical activity guidelines and ground reality: A real world analysis of physical activity profile of cancer survivors. Journal of Clinical Oncology. 36: 105-105. DOI: 10.1200/Jco.2018.36.7_Suppl.105 |
0.376 |
|
| 2018 |
Fletcher S, Alsaid N, Katragadda C, Martin J, Babiker HM, Algotar AM, McBride A, MacDonald K, Abraham I. Risk of biochemical recurrence (BCR) in prostate cancer (PCa) patients (pts) with perineural invasion (PNI): Systematic review and meta-analysis. Journal of Clinical Oncology. 36: e17060-e17060. DOI: 10.1200/Jco.2018.36.15_Suppl.E17060 |
0.46 |
|
| 2016 |
Algotar AM, Singh P, Billins J, Thomazin G. Change in prostate biopsy outcomes and costs of care for prostate cancer in underserved population after changes in USPSTF guidelines. Journal of Clinical Oncology. 34: 1548-1548. DOI: 10.1200/Jco.2016.34.15_Suppl.1548 |
0.66 |
|
| 2015 |
Algotar AM, Behnejad R, Singh P, Thompson PA, Hsu CH, Stratton SP. EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN. The Journal of Frailty & Aging. 4: 107-110. PMID 26366377 DOI: 10.14283/Jfa.2015.48 |
0.351 |
|
| 2015 |
Algotar A, Cress A, Nagle R, Sokoloff M, Singh P, Behnejad R, Stratton S. Association of ERG-PTEN expression profile of prostate biopsy with PSA velocity. Journal of Clinical Oncology. 33: 92-92. DOI: 10.1200/Jco.2015.33.7_Suppl.92 |
0.731 |
|
| 2015 |
Algotar AM, Cress A, Nagle R, Sokoloff M, Behnejad R, Drinkwitz D, Lodhia N, Thompson P, Stratton SP. DNA damage and repair markers to improve accuracy of prostate cancer diagnosis and identification of aggressive disease. Journal of Clinical Oncology. 33: e16012-e16012. DOI: 10.1200/Jco.2015.33.15_Suppl.E16012 |
0.628 |
|
| 2015 |
Algotar AM, Behnejad R, Stratton MS, Stratton S. Can smoking lead to delay in diagnosis of prostate cancer Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16011 |
0.706 |
|
| 2014 |
Algotar AM, Behnejad R, Stratton MS, Stratton SP. Chronic use of NSAIDs and/or statins does not affect PSA or PSA velocity in men at high risk for prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2196-8. PMID 25060669 DOI: 10.1158/1055-9965.EPI-14-0605 |
0.693 |
|
| 2014 |
Algotar AM, Cress AE, Nagle RB, Drinkwitz D, Lodhia NS, Thompson PA, Stratton SP. Abstract 1856: DNA damage and repair markers (H2AX and RAD51) improve accuracy of prostate cancer diagnosis and improve identification of aggressive disease Cancer Research. 74: 1856-1856. DOI: 10.1158/1538-7445.Am2014-1856 |
0.731 |
|
| 2014 |
Algotar AM, Stratton MS, Harryman WL, Cress AE. Prevention of prostate cancer Fundamentals of Cancer Prevention, Third Edition. 491-531. DOI: 10.1007/978-3-642-38983-2_16 |
0.655 |
|
| 2013 |
Nagle RB, Algotar AM, Cortez CC, Smith K, Jones C, Sathyanarayana UG, Yun S, Riley J, Nagy D, Dittamore R, Dalkin B, Brosh L, Pestano G. ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. The Prostate. 73: 1233-40. PMID 23653096 DOI: 10.1002/Pros.22675 |
0.631 |
|
| 2013 |
Algotar AM, Hsu CH, Singh P, Stratton SP. Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer Journal of Diabetes. 5: 465-470. PMID 23489776 DOI: 10.1111/1753-0407.12041 |
0.507 |
|
| 2013 |
Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. The Prostate. 73: 328-35. PMID 22887343 DOI: 10.1002/Pros.22573 |
0.757 |
|
| 2013 |
Singh P, Algotar AM, Bracamonte ER. Prostatic Small Cell Carcinoma: Diagnosis and Management Journal of Cancer Therapy. 4: 804-810. DOI: 10.4236/Jct.2013.43097 |
0.581 |
|
| 2013 |
Algotar AM, Sokoloff M, Hsu C, Singh P, Stratton SP. Negative association of smoking with PSA and PSA velocity. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E16060 |
0.573 |
|
| 2013 |
Algotar AM, Hsu CH, Stratton SP. Abstract 3615: Does selenium supplementation increase serum glucose levels in men at high risk for prostate cancer. Cancer Research. 73: 3615-3615. DOI: 10.1158/1538-7445.Am2013-3615 |
0.568 |
|
| 2012 |
Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP. Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity. Internal Medicine Journal. 42: 374-80. PMID 21395960 DOI: 10.1111/J.1445-5994.2011.02473.X |
0.741 |
|
| 2012 |
Brosh L, Abril E, Cortez C, Algotar A, Meek W, Dexter E, Dittamore R, Dalkin B, Nagle R, Pestano G. 427 Correlation between ERG rearrangement and PTEN loss with capsular penetration in prostate cancer European Urology Supplements. 11: e427-e427a. DOI: 10.1016/S1569-9056(12)60424-2 |
0.615 |
|
| 2011 |
Algotar AM, Stratton SP, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Thompson PA. Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer. American Journal of Men's Health. 5: 272-8. PMID 21613377 DOI: 10.1177/1557988310390030 |
0.731 |
|
| 2011 |
Algotar AM, Stratton MS, Xu MJ, Dalkin BL, Nagle RB, Hsu CH, Ahmann FR, Clark LC, Stratton SP. Dose-dependent effects of selenized yeast on total selenium levels in prostatic tissue of men with prostate cancer. Nutrition and Cancer. 63: 1-5. PMID 21128179 DOI: 10.1080/01635581.2010.516476 |
0.72 |
|
| 2010 |
Algotar AM, Stratton MS, Stratton SP, Hsu CH, Ahmann FR. No effect of selenium supplementation on serum glucose levels in men with prostate cancer. The American Journal of Medicine. 123: 765-8. PMID 20670733 DOI: 10.1016/J.Amjmed.2010.02.018 |
0.56 |
|
| 2010 |
Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prevention Research (Philadelphia, Pa.). 3: 1035-43. PMID 20647337 DOI: 10.1158/1940-6207.Capr-09-0143 |
0.757 |
|
| 2010 |
Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. The Prostate. 70: 883-8. PMID 20135645 DOI: 10.1002/Pros.21122 |
0.717 |
|
| 2008 |
Stratton M, Algotar AM, Ranger-Moore J, Slate E, Hsu P, Stratton SP, Thompson PA, Ahmann FR. Phase IIb clinical trial of selenium in prostate cancer patients on active surveillance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5060. PMID 27948781 DOI: 10.1200/Jco.2008.26.15_Suppl.5060 |
0.671 |
|
| Show low-probability matches. |